Zoom has announced that it will be going public on April 18th 2019. This has generated substantial hype and lead to a valuation of $36 per share tomorrow. In this article I will discuss; Potential … [Read more...] about Should You Buy The ZOOM IPO?
Whats Happening? Novavax Inc. (Nasdaq: NVAX) is getting attention lately as investors debate the potential of the company’s respiratory syncytial virus (RSV) vaccination “ResVax”, a proposed 1:20 … [Read more...] about NVAX At A Glance
You voted and we heard you. After my initial article on a few noteworthy results from AACR 2019, we asked you the subscribers to choose one of the four companies that you would like to learn more … [Read more...] about An In-Depth Assessment Of TG Therapeutics
Background Investors have recently been faced with many headwinds in the first half of 2019. With potential threats to Bulls positions constantly surfacing, 2019 has been volatile to say the least. … [Read more...] about Why I’m Bullish With Brexit
In a new series for MS Money Moves Premium Members, Chris Stang a PharmD candidate at the University of Findlay and Nationwide Pharmacy Intern will evaluate a few pieces of data releases from health … [Read more...] about Eye-Catching Results at AACR 2019: A Quick Road Map
At the end of January, the small-cap biotechnology company AVEO Oncology (AVEO) updated investors on the delayed timeline for filing with FDA for their lead compound tivozanib. This news led to a … [Read more...] about Evaluating the Merits of AVEO’s Potential Purchase
2019 is undoubtedly the year of gene editing. All three major gene editing biotechnology companies have kicked the year off with monumental studies. As the results of these experiments get published, … [Read more...] about Sangamo (NASDAQ: SGMO) Vs. CRISPR Therapeutics (NASDAQ: CRSP): The Best Gene Editing Stock
From designer babies to malaria-resistant mosquitoes, a future where humans can dive into the basic building blocks of all life and manipulate it for our advantage is not too far away. Startups, … [Read more...] about Illumina: Growth at a Fair Price?
Today Adma Biologics (Nasdaq: ADMA) sold off ~10% closing at $3.50. Most of us already in Adma were not phased. Personally, I saw this as a healthy pullback. Since February 1st ADMA has gained 25% … [Read more...] about ADMA Presents Potential Entry For Investors On The Sideline
Amarin (Nasdaq: AMRN) made perhaps the biggest splash in the small-cap biopharmaceutical space last year by announcing trial results from its long-running REDUCE-IT study. The company has a market cap … [Read more...] about Amarin Corporation – A Whale of a Story